IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC PROGNOSTIC FACTORS FOR EARLY-STAGE INVASIVE BLADDER CANCER
https://doi.org/10.17650/1726-9776-2011-7-3-20-24
Abstract
Bladder cancer (BC) is one of the most common malignancies. More than 90 % of the notified cases are morphologically diagnosed as transitional cell carcinoma; moreover, over 70 % of them are the early stages (Ta, Tis, and T1) of the disease. Patients with diagnosed T1 tumor are deemed to be the most difficult group of patients with early-stage BC. Despite the generally good prognosis of the course of this stage of BC after performed therapy, the tumor recurs in most patients and progresses to a more disseminated stage in 15–20 %. In this connection, there is a continuous search for the prognostic markers associated with the poor prognosis of the disease. A number of morphological, immunohistochemical, and molecular signs that, according to the investigators’ data, correlate with the risk for BC recurrence and progression have been identified. Nonetheless, a diagnostic testing algorithm that permits the prediction of the course of the disease from primary histological data remains to be elaborated. There should be further investigations that enable one to develop an informative panel of diagnostic and prognostic markers that allow a pathologist to correctly define the stage and prognosis of the disease and a clinician to choose an optimal treatment policy for each patient.
About the Authors
I. V. Chernyshev
Research Institute of Urology, Moscow
Russian Federation
Russian Federation
G. D. Efremov
Research Institute of Urology, Moscow
Russian Federation
Russian Federation
A. S. Tertychnyi
I.M. Sechenov First Moscow Medical University
Russian Federation
Russian Federation
D. V. Perepechin
Research Institute of Urology, Moscow
Russian Federation
Russian Federation
References
1. Чернышев И.В. Оптимизация подходов диагностики и лечения рака мочевого пузыря: дис. ... д-ра мед. наук. М., 2004. 369 с.
2. Франк Г.А., Завалишина Л.Э., Андреева Ю.Ю. Уточняющая диагностика рака с использованием иммуногистохимического определения маркеров. Медицинская технология. М., 2009.
3. Cheng L., Montironi R., Davidson D., Lopez-Beltran A. Staging and reporting of urotelial carcinoma of the urinary bladder. Modern Path 2009;22:70–95.
4. Tosoni I., Wagner U., Sauter G. et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000;85:48–53.
5. Bol M.G., Baak J.P., Buhr-Wildhagen S. et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291–4.
6. Angulo J.C., Lopez J.I., Grignon D.J., Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage PT1 bladder cancer. Urology 1995;45:47–53.
7. Holmang S., Hedelin H., Anderstrom C. et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800–4.
8. Hermann G.G., Horn T., Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage PT1 transitional cell bladder cancer. J Urol 1998;159:91–4.
9. Epstein J.I., Amin M.B., Reuter V.R. et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48.
10. Cheng L., Neumann R.M., Weaver A.L. et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999;17:3182–7.
11. Andius P., Johansson S.L., Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007;70:758–62.
12. Cho K.S., Seo H.K., Joung J.Y. et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol (2009);182(6):2625−30.
13. Lopez J.I., Angulo J.A. Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance. Int Urol Nephrol (2009) 41:847−54.
14. Mhawech P., Iselin C., Pelte M.F. Value of immunohistochemistry in staging T1 urothelial bladder carcinoma. Eur Urol 2002;42:459–63.
15. Tamas E.F., Epstein J.I. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains. Am J Surg Pathol 2007;31:390–7.
16. Bovia I., Al-Quran S., Rosser C. et al. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder cancer. Histopat 2010;56:951−6.
17. Council L., Hameed O. Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin and vimentin in staging of bladder carcinoma. Mod Path 2009;22:639−50.
18. Goebel P., Groshen S., Bernd J. et al. p53 immunohistochemistry in bladder cancer — a new approach to an old question. Urol Oncol 2010, 28(4):377−88.
19. Mhawech P., Greloz V., Oppikofer C. et al. expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 2004;100:2367−75.
20. Mhawech-Fauceglia P., Fischer G., Becka A. et al. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006; 32(4):439−44.
21. Mhawech-Fauseglia P., Cheney R., Schwaller J. Genetic alterations in urothelial bladder carcinoma. Cancer 2006;106:1205−16.
22. Mhawech-Fauseglia P., Fisher G., Alvarez V. et al. Predicting outcome in minimally invasive urothelial bladder carcinoma using biomarkers: a high throughput tissue microarray analysis. BJU 2007; 100:1182−7.
23. Shariat S., Bolenz C., Godoy G. et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78−84.
24. Bryan R., Zeegers M., James N. et al. Biomarkers in bladder cancer. BJU Int 2009;105:608−13.
25. Fadl-Elmula I., Gorunova L., Mandahl N. et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000; 29:256–65.
26. Hoffmann M.J., Florl A.R., Seifert H.H., Schulz W.A. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114:406–13.
27. Knowels M. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27(3):361−73.
28. Chow N.H., Chan S.H., Tzai T.S. et al. Expression profiles of ErbB family receptors and prognosis in transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7:1957–62.
29. Nicholson B.E., Frierson H.F., Conaway M.R. et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004; 64:7813–21.
30. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol 2008; 42 (Suppl 218):154−65.
31. Mian С., Lodde M., Comploj E. et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006;59:984–7.
32. Simonetti S., Russo R., Ciancia C. et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and FISH analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009:17(3):198−205.
33. del Rey J., Prat E., Ponsa I. et al. Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors. BMC Cancer 2010;10:280−91.
34. Bollman D., Bollman M., Bankfalvi A. et al. Quantitative molecular grading of bladder tumours: A tool for objective assessment of the biological potential of urothelial neoplasias. Oncol Rep 2009;21:39−47.
35. Lindgren D., Frikvesi A., Guidionsson S. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70(9):3463−72.
Review
For citations:
Chernyshev I.V., Efremov G.D., Tertychnyi A.S., Perepechin D.V. IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC PROGNOSTIC FACTORS FOR EARLY-STAGE INVASIVE BLADDER CANCER. Cancer Urology. 2011;7(3):20-24. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-3-20-24
Views:
717
Email this article 